- Provides update on the Phase I/IIa trial evaluating lead asset BT1718 in patients with advanced solid tumors
- Successfully completed initial public offering (IPO) raising gross proceeds of $64.9 million
- Strengthened Board of Directors and clinical leadership team
Bicycle Therapeutics plc, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycles®) product platform, today reported financial results for the second quarter ended June 30, 2019 and provided a clinical update.
“The second quarter of this year was marked by the completion of our initial public offering, placing us in a solid financial position to advance our novel pipeline of Bicycle drug candidates through the clinic,” said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics. “We are pleased with the progress that our pipeline has made over the last quarter, including BT1718, which continues to progress in Phase I dose escalation. We believe that Bicycles, because of their low molecular weight and high affinity and selectivity, could provide meaningful efficacy to patients suffering from cancer and could avoid the toxicities associated with other classes of highly potent anti-cancer drugs, and we look forward to providing updates on our progress.”
View the full source version here.
(+44) 1223 496 000
Babraham Bioscience Technologies Ltd
Babraham Research Campus
CB22 3AT, United Kingdom
01223 813 557